Bonaventure Banyurwabuke

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
This paper aims to compare the approved second-line treatment options in metastatic renal cell carcinoma. A network meta-analysis (NMA) using the frequentist approach and generalized pairwise modeling was computed for the approved drugs in this setting. The results of this NMA showed that the combination of lenvatinib and everolimus yielded the lowest(More)
  • 1